|
Virtual Meetings 2022
Meet The Professor: Optimizing the Management of Small Cell Lung CancerFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Carl M Gay, MD, PhD Assistant Professor Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Jacob Sands, MD Physician Dana-Farber Cancer Institute Assistant Professor Harvard Medical School Boston, Massachusetts SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by an educational grant from Jazz Pharmaceuticals Inc. Agenda
MODULE 1: First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) MODULE 2: Selection and Sequencing of Therapy for Patients with Relapsed SCLC MODULE 3: Safety and Tolerability of Available Therapies for SCLC
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Gay — Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Jazz Pharmaceuticals Inc, Monte Rosa Therapeutics; Consulting Agreement: Kisoji Biotechnology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP; Speakers Bureau: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Jazz Pharmaceuticals Inc. Dr Sands — Advisory Committee: Curadev; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Medtronic Inc, PharmaMar, Takeda Pharmaceuticals USA Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporter These activities are supported by an educational grant from Jazz Pharmaceuticals Inc. |